GSK’s Malaria Vaccine Containing Agenus’ QS-21 Stimulon® Receives Positive Opinion from European Regulators for Prevention of Malaria in Young Children in Sub-Saharan Africa

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. IBM
3. PRIM
4. MU
5. DPZ
6. NAVN
7. DFTX
8. META
9. IMNN
10. ACN

Go back to GSK’s Malaria Vaccine Containing Agenus’ QS-21 Stimulon® Receives Positive Opinion from European Regulators for Prevention of Malaria in Young Children in Sub-Saharan Africa

Agenus (AGEN) Announces Positive Opinion on Glaxo's (GSK) Malaria Vaccine from EMA

July 24, 2015 6:00 AM EDT

Agenus (NASDAQ: AGEN) announced that GlaxoSmithKline (NYSE: GSK) received a positive opinion for its Malaria vaccine candidate from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The vaccine candidate, named Mosquirix (RTS,S) is the first QS-21 Stimulon containing product to receive a positive regulatory decision. Agenus adjuvant QS-21 is designed to increase immune response to antigens in vaccines. The positive opinion signals that... More